Johnson & JohnsonRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Johnson & Johnson (JNJ) reported revenue of $25.31B in Q2 2026, with Innovative Medicine its largest revenue segment at 65%.
Johnson & JohnsonJohnson & Johnson sells Innovative Medicine (Darzalex, Tremfya, Carvykti, and a shrinking Stelara franchise) and MedTech (surgery, orthopaedics, cardiovascular, and vision). It has announced an intent to separate Orthopaedics as DePuy Synthes.
Johnson & Johnson (JNJ) is a Pharmaceuticals company. Johnson & Johnson sells Innovative Medicine (Darzalex, Tremfya, Carvykti, and a shrinking Stelara franchise) and MedTech (surgery, orthopaedics, cardiovascular, and vision). It has announced an intent to separate Orthopaedics as DePuy Synthes. It was founded in 1886, is headquartered in New Brunswick, New Jersey and employs about 138,200 people.
As of 2026-Q2, Johnson & Johnson's revenue breaks down across Innovative Medicine (65%), MedTech (35%). See the revenue-by-segment chart for the full mix.
Track Johnson & Johnson's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated October 9, 2026.
Sterling groups Johnson & Johnson in the Healthcare industry, alongside Bristol Myers Squibb (BMY), Viatris (VTRS) and Zoetis (ZTS).
If you are researching Johnson & Johnson, also look at Bristol Myers Squibb (BMY), Viatris (VTRS) and Zoetis (ZTS). You can compare all of them side by side or browse the full Healthcare industry on Sterling.
Q3 2016-Q2 2026
Q3 2016-Q2 2026